NASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $7.97 -0.09 (-1.12%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.72▼$8.2150-Day Range$7.58▼$10.5452-Week Range$5.67▼$30.99Volume527,812 shsAverage Volume972,391 shsMarket Capitalization$415.11 millionP/E RatioN/ADividend YieldN/APrice Target$30.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get EyePoint Pharmaceuticals alerts: Email Address EyePoint Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside284.3% Upside$30.63 Price TargetShort InterestBearish18.20% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 4 Articles This WeekInsider TradingSelling Shares$116,948 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.33) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 starsMedical Sector409th out of 910 stocksAnalytical Instruments Industry15th out of 26 stocks 4.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyePoint Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about EyePoint Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.20% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently decreased by 0.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 1.9 News and Social Media Coverage News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest5 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have sold 484.83% more of their company's stock than they have bought. Specifically, they have bought $19,997.00 in company stock and sold $116,948.00 in company stock.Percentage Held by InsidersOnly 4.74% of the stock of EyePoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about EyePoint Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.33) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about EyePoint Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More EYPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYPT Stock News HeadlinesAugust 22, 2024 | insidertrades.comWendy F. Dicicco Buys 2,567 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) StockSeptember 6 at 5:49 AM | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded by StockNews.com to SellSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 4 at 7:00 AM | globenewswire.comEyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of DirectorsAugust 29, 2024 | msn.comJefferies Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy RecommendationAugust 29, 2024 | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Jefferies Financial GroupAugust 29, 2024 | bizjournals.comFDA warns Watertown biotech over ‘significant violations’ at manufacturing facilityAugust 29, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: A Buy Rating with a $15 Price Target Amid Promising Duravyu Prospects and Market GrowthSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 27, 2024 | globenewswire.comEyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesAugust 17, 2024 | markets.businessinsider.comOutperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu DevelopmentsAugust 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 15, 2024 | finance.yahoo.comSome Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) EstimatesAugust 10, 2024 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their EstimatesAugust 9, 2024 | finance.yahoo.comIs EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?August 9, 2024 | markets.businessinsider.comOptimistic ‘Buy’ Rating for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial ProspectsAugust 8, 2024 | globenewswire.comEyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 7, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsSee More Headlines Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees120Year Founded1987Price Target and Rating Average Stock Price Target$30.63 High Stock Price Target$44.00 Low Stock Price Target$15.00 Potential Upside/Downside+284.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,790,000.00 Net Margins-172.29% Pretax Margin-172.13% Return on Equity-43.24% Return on Assets-29.72% Debt Debt-to-Equity RatioN/A Current Ratio4.75 Quick Ratio4.69 Sales & Book Value Annual Sales$50.39 million Price / Sales8.24 Cash FlowN/A Price / Cash FlowN/A Book Value$5.66 per share Price / Book1.41Miscellaneous Outstanding Shares52,084,000Free Float49,615,000Market Cap$415.11 million OptionableOptionable Beta1.59 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Jay S. Duker M.D. (Age 65)President, CEO & Director Comp: $848.5kDr. John B. Landis M.S. (Age 71)Ph.D., Interim Head of R&D and Director Comp: $63.75kMr. Michael Pine (Age 47)Chief Business Officer Comp: $764.85kMr. George O. Elston (Age 59)Executive VP & CFO Comp: $743.86kMr. Michael J. MaciocioSenior Vice President of Manufacturing & OperationsMr. Ron I. Honig Esq.Chief Legal Officer & Company SecretaryMs. Jennifer LeonardChief People Officer & Senior VP of ITMr. David Scott Jones (Age 56)Senior VP & Chief Commercial Officer Comp: $672.08kMs. Isabelle LefebvreChief Regulatory OfficerDr. Marcia Sellos-Moura Ph.D.Senior Vice President of Program LeadershipMore ExecutivesKey CompetitorsFluidigmNASDAQ:FLDMHarvard BioscienceNASDAQ:HBIOTranscatNASDAQ:TRNSStandard BioToolsNASDAQ:LABCytek BiosciencesNASDAQ:CTKBView All CompetitorsInsiders & InstitutionsWendy F DiciccoBought 2,567 shares on 8/20/2024Total: $19,996.93 ($7.79/share)Fiera Capital CorpBought 5,920 shares on 8/19/2024Ownership: 1.300%Point72 Asset Management L.P.Bought 630,769 shares on 8/19/2024Ownership: 1.211%Perceptive Advisors LLCBought 50,628 shares on 8/16/2024Ownership: 1.229%The Manufacturers Life Insurance Company Sold 8,496 shares on 8/15/2024Ownership: 0.131%View All Insider TransactionsView All Institutional Transactions EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? EyePoint Pharmaceuticals' stock was trading at $23.11 at the beginning of 2024. Since then, EYPT stock has decreased by 65.5% and is now trading at $7.97. View the best growth stocks for 2024 here. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its earnings results on Wednesday, August, 7th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.03. The business earned $9.48 million during the quarter, compared to analyst estimates of $11.61 million. EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative trailing twelve-month return on equity of 43.24%. When did EyePoint Pharmaceuticals' stock split? Shares of EyePoint Pharmaceuticals reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are EyePoint Pharmaceuticals' major shareholders? EyePoint Pharmaceuticals' top institutional investors include Deerfield Management Company L.P. Series C (1.69%), Fiera Capital Corp (1.30%), Fiera Capital Corp (1.30%) and Perceptive Advisors LLC (1.23%). Insiders that own company stock include Ew Healthcare Partners, LP, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine and David R Guyer. View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX) and Catalyst Pharmaceuticals (CPRX). This page (NASDAQ:EYPT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
